Literature DB >> 16376658

Vitrectomy in the treatment of uveitis.

Matthias Becker1, Janet Davis.   

Abstract

PURPOSE: To assess the evidence that pars plana vitrectomy (PPV) is useful in improving vision, reducing disease activity, or ameliorating cystoid macular edema (CME) in patients with uveitis.
DESIGN: Review of the literature.
METHODS: A Medline search was conducted for relevant articles published in English, German, or French. Articles were analyzed for content and evidence level.
RESULTS: A total of 44 interventional case series published between 1981 and 2005 were identified that included 1575 patients (1762 eyes). Evidence level was grade CII-3 indicating possibly improved clinical outcomes with fair or poor evidence. The average age of patients was 36 years with a median duration of uveitis before surgery of 48 months and a median follow-up of 1.9 years. Intermediate uveitis was present in 841 eyes. Cystoid macular edema and cataract were common co-morbidities, and there were large numbers of additional surgical procedures. Visual outcomes in 39 articles were stated as improved in 708 eyes (68%), unchanged in 202 eyes (20%), and worsened in 124 eyes (12%). Reduction in systemic medication following PPV was reported in 25 studies. The median reported percentage of patients per study with CME was 36% preoperatively and 18% postoperatively.
CONCLUSIONS: Based on the evidence in the literature, PPV is possibly relevant to the outcomes of improving vision and reducing inflammation and CME. Randomized, controlled, collaborative trials or hypothesis-based case series with precise outcome measures that incorporate control groups would improve the quality of evidence supporting PPV as an adjunct to the medical treatment of uveitis.

Entities:  

Mesh:

Year:  2005        PMID: 16376658     DOI: 10.1016/j.ajo.2005.07.017

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  18 in total

1.  Vitreous levels of somatostatin in patients with chronic uveitic macular oedema.

Authors:  A Fonollosa; E Coronado; R Catalan; M Gutierrez; C Macia; M A Zapata; N Martinez-Alday; R Simo; J Garcia-Arumi
Journal:  Eye (Lond)       Date:  2012-08-10       Impact factor: 3.775

Review 2.  Intermediate uveitis.

Authors:  B Manohar Babu; S R Rathinam
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

3.  [Intermediate uveitis: guidelines of the German Ophthalmological Society and the Professional Association of German Ophthalmologists].

Authors:  F Mackensen; L Baydoun; J Garweg; A Heiligenhaus; T Hudde
Journal:  Ophthalmologe       Date:  2014-11       Impact factor: 1.059

4.  An Outbreak of Endogenous Fungal Endophthalmitis Among Intravenous Drug Abusers in New England.

Authors:  Aubrey R Tirpack; Jay S Duker; Caroline R Baumal
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

5.  [Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists for intravitreal treatment of macular edema in uveitis: Date: 02/07/2014].

Authors:  A Heiligenhaus; B Bertram; C Heinz; L Krause; U Pleyer; J Roider; S Sauer; S Thurau
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

Review 6.  Chronic non-infectious uveitis in the elderly: epidemiology, pathophysiology and management.

Authors:  Rajen Gupta; Philip I Murray
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 7.  [Guidelines nr. 24a intermediate uveitis].

Authors: 
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

8.  [Therapy of intermediate uveitis].

Authors:  D Doycheva; C Deuter; M Zierhut
Journal:  Ophthalmologe       Date:  2014-12       Impact factor: 1.059

9.  Uveitic Macular Edema: Treatment Update.

Authors:  Raquel Goldhardt; Bradley Simon Rosen
Journal:  Curr Ophthalmol Rep       Date:  2016-02-18

10.  Remission of Intermediate Uveitis: Incidence and Predictive Factors.

Authors:  John H Kempen; Dina Y Gewaily; Craig W Newcomb; Teresa L Liesegang; R Oktay Kaçmaz; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; H Nida Sen; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Abhishek Payal; Tonetta D Fitzgerald
Journal:  Am J Ophthalmol       Date:  2016-01-06       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.